• Users Online: 785
  • Print this page
  • Email this page
Year : 2021  |  Volume : 4  |  Issue : 2  |  Page : 121-126

Emergence of SBRT in borderline resectable pancreatic cancer: Is it the way forward?

1 Department of Radiation Oncology, Nanavati-Max Superspeciality Hospital, Mumbai, Maharashtra, India
2 Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Shreyasee Karmakar
Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jco.jco_22_21

Rights and Permissions

Pancreatic cancers are aggressive cancers with poor survival outcomes and few effective treatment modalities. The previously used protracted chemo-radiotherapy (CTRT) regimens have not had encouraging results. Stereotactic body radiotherapy (SBRT) has shown encouraging results in the treatment paradigm of borderline resectable pancreatic cancers. Though body of level I evidence is weak currently, studies have shown better resectability with negative margins with neoadjuvant SBRT. Precise contouring, good image guidance, strict quality assurance, and multi-disciplinary spatial co-operation are crucial for its success. High biologically effective dose, smaller margins, short duration of treatment, and strategic sequencing are the key to better outcomes.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal